Shares of PaxMedica, Inc. (NASDAQ:PXMD – Get Free Report) traded down 4.3% on Thursday . The company traded as low as $0.21 and last traded at $0.22. 16,461 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 1,056,708 shares. The stock had previously closed at $0.23.
PaxMedica Price Performance
The stock has a 50 day simple moving average of $0.25 and a two-hundred day simple moving average of $0.42.
PaxMedica (NASDAQ:PXMD – Get Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). On average, equities research analysts predict that PaxMedica, Inc. will post -1.09 EPS for the current year.
About PaxMedica
PaxMedica, Inc, a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome.
Further Reading
- Five stocks we like better than PaxMedica
- What is a Dividend King?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- What Investors Need to Know About Upcoming IPOs
- MarketBeat Week in Review – 8/5 – 8/9
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.